-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Wedbush Comments on Kiniksa Pharmaceuticals, Ltd.'s Q4 2022 Earnings (NASDAQ:KNSA)
Wedbush Comments on Kiniksa Pharmaceuticals, Ltd.'s Q4 2022 Earnings (NASDAQ:KNSA)
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) – Analysts at Wedbush lifted their Q4 2022 earnings per share estimates for Kiniksa Pharmaceuticals in a report issued on Wednesday, August 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.27) per share for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($1.46) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q1 2023 earnings at ($0.29) EPS, Q2 2023 earnings at ($0.45) EPS, Q3 2023 earnings at ($0.45) EPS, Q4 2023 earnings at ($0.44) EPS, FY2023 earnings at ($1.63) EPS, FY2024 earnings at ($1.46) EPS and FY2025 earnings at ($0.89) EPS.
Get Kiniksa Pharmaceuticals alerts:Kiniksa Pharmaceuticals Stock Up 14.7 %
Shares of KNSA opened at $13.41 on Monday. Kiniksa Pharmaceuticals has a 12-month low of $7.36 and a 12-month high of $15.24. The firm has a market capitalization of $928.99 million, a PE ratio of -8.28 and a beta of -0.12. The stock's fifty day simple moving average is $9.96 and its 200-day simple moving average is $10.02.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $44,000. Rockefeller Capital Management L.P. increased its holdings in shares of Kiniksa Pharmaceuticals by 666.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 5,750 shares of the company's stock worth $67,000 after acquiring an additional 5,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Kiniksa Pharmaceuticals by 290.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,164 shares of the company's stock worth $84,000 after acquiring an additional 5,327 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $86,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $190,000. Institutional investors and hedge funds own 42.57% of the company's stock.About Kiniksa Pharmaceuticals
(Get Rating)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Featured Articles
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- Electric Vehicles Can Drive Alcoa Stock Higher
- Can Airbnb Still Thrive in a Recession?
- What to Expect from the Markets in a Recession
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- MarketBeat: Week in Review 8/1 – 8/5
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) – Analysts at Wedbush lifted their Q4 2022 earnings per share estimates for Kiniksa Pharmaceuticals in a report issued on Wednesday, August 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.27) per share for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($1.46) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q1 2023 earnings at ($0.29) EPS, Q2 2023 earnings at ($0.45) EPS, Q3 2023 earnings at ($0.45) EPS, Q4 2023 earnings at ($0.44) EPS, FY2023 earnings at ($1.63) EPS, FY2024 earnings at ($1.46) EPS and FY2025 earnings at ($0.89) EPS.
Kiniksa製藥有限公司(納斯達克代碼：KNSA-GET Rating)-韋德布什的分析師在8月3日星期三發佈的一份報告中上調了對Kiniksa製藥公司2022年第四季度每股收益的預期。韋德布什分析師D.尼倫加滕現在預測，該公司本季度每股收益為0.27美元，高於此前預測的0.36美元。對Kiniksa製藥公司目前全年收益的普遍估計是每股1.46美元。韋德布什還發布了對Kiniksa製藥公司2023年第一季度每股收益(0.29美元)、2023年第二季度每股收益(0.45美元)、2023年第三季度每股收益(0.45美元)、2023年第四季度每股收益(0.44美元)、2023財年每股收益(1.63美元)、2024財年每股收益(1.46美元)和2025財年每股收益(0.89美元)的預期。
Kiniksa Pharmaceuticals Stock Up 14.7 %
Kiniksa製藥類股上漲14.7%
Shares of KNSA opened at $13.41 on Monday. Kiniksa Pharmaceuticals has a 12-month low of $7.36 and a 12-month high of $15.24. The firm has a market capitalization of $928.99 million, a PE ratio of -8.28 and a beta of -0.12. The stock's fifty day simple moving average is $9.96 and its 200-day simple moving average is $10.02.
週一，KNSA的股價開盤報13.41美元。Kiniksa PharmPharmticals的12個月低點為7.36美元，12個月高位為15.24美元。該公司市值為9.2899億美元，市盈率為-8.28，貝塔係數為-0.12。該股的50日簡單移動均線為9.96美元，200日簡單移動均線為10.02美元。
Hedge Funds Weigh In On Kiniksa Pharmaceuticals
對衝基金買入Kiniksa製藥公司
About Kiniksa Pharmaceuticals
關於Kiniksa製藥公司
(Get Rating)
(獲取評級)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Kiniksa製藥有限公司是一家生物製藥公司，專注於發現、獲得、開發治療藥物，並將其商業化，用於治療世界各地嚴重未得到滿足的醫療需求的衰弱疾病患者。它的候選產品包括用於治療複發性心包炎的ARCALYST，這是一種炎症性心血管疾病，是一種治療複發性心包炎的藥物；Mavrilimumab，一種完成了治療鉅細胞動脈炎的第二階段臨牀試驗的單抗；Vixarelimab，一種處於2a期臨牀試驗的單抗，用於治療慢性炎症性皮膚疾病結節性瘙癢；以及KPL-404，一種CD40-CD154相互作用的單抗抑制物，一種對B細胞成熟、免疫球蛋白類別轉換和1型免疫反應至關重要的T細胞共刺激信號。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- Electric Vehicles Can Drive Alcoa Stock Higher
- Can Airbnb Still Thrive in a Recession?
- What to Expect from the Markets in a Recession
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- MarketBeat: Week in Review 8/1 – 8/5
- 免費獲取StockNews.com關於Kiniksa製藥公司(KNSA)的研究報告
- 電動汽車可以推動美國鋁業股價走高
- 愛彼迎還能在經濟衰退中茁壯成長嗎？
- 對衰退中的市場有什麼期待
- 康菲石油股價上漲，第二季度營收強勁
- MarketBeat：回顧中的一週8/1-8/5
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Kiniksa製藥日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Kiniksa製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧